Takeda Pharmaceutical Co Ltd ADR (TAK) - Total Assets
Based on the latest financial reports, Takeda Pharmaceutical Co Ltd ADR (TAK) holds total assets worth $15.42 Trillion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Takeda Pharmaceutical Co Ltd ADR cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Takeda Pharmaceutical Co Ltd ADR - Total Assets Trend (2000–2025)
This chart illustrates how Takeda Pharmaceutical Co Ltd ADR's total assets have evolved over time, based on quarterly financial data. See Takeda Pharmaceutical Co Ltd ADR (TAK) shareholders funds for net asset value and shareholders' equity analysis.
Takeda Pharmaceutical Co Ltd ADR - Asset Composition Analysis
Current Asset Composition (March 2025)
Takeda Pharmaceutical Co Ltd ADR's total assets of $15.42 Trillion consist of 17.7% current assets and 82.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $233.74 Billion | 2.7% |
| Accounts Receivable | $725.25 Billion | 5.1% |
| Inventory | $1.22 Trillion | 8.5% |
| Property, Plant & Equipment | $1.97 Trillion | 13.8% |
| Intangible Assets | $3.63 Trillion | 25.5% |
| Goodwill | $5.32 Trillion | 37.4% |
Asset Composition Trend (2000–2025)
This chart illustrates how Takeda Pharmaceutical Co Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TAK company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Takeda Pharmaceutical Co Ltd ADR's current assets represent 17.7% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 2.7% of total assets in 2025, up from 0.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 62.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 37.4% of total assets.
Takeda Pharmaceutical Co Ltd ADR Competitors by Total Assets
Key competitors of Takeda Pharmaceutical Co Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
Takeda Pharmaceutical Co Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 1.31 | 1.53 |
| Quick Ratio | 0.65 | 0.72 | 1.10 |
| Cash Ratio | 0.25 | 0.24 | 0.00 |
| Working Capital | $506.60 Billion | $656.32 Billion | $939.72 Billion |
Takeda Pharmaceutical Co Ltd ADR - Advanced Valuation Insights
This section examines the relationship between Takeda Pharmaceutical Co Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.08 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.7% |
| Total Assets | $14.25 Trillion |
| Market Capitalization | $52.60 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Takeda Pharmaceutical Co Ltd ADR's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Takeda Pharmaceutical Co Ltd ADR's assets decreased by 5.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Takeda Pharmaceutical Co Ltd ADR (2000–2025)
The table below shows the annual total assets of Takeda Pharmaceutical Co Ltd ADR from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $14.25 Trillion | -5.70% |
| 2024-03-31 | $15.11 Trillion | +8.25% |
| 2023-03-31 | $13.96 Trillion | +5.92% |
| 2022-03-31 | $13.18 Trillion | +2.06% |
| 2021-03-31 | $12.91 Trillion | +0.71% |
| 2020-03-31 | $12.82 Trillion | -7.58% |
| 2019-03-31 | $13.87 Trillion | +237.82% |
| 2018-03-31 | $4.11 Trillion | -5.72% |
| 2017-03-31 | $4.36 Trillion | +13.90% |
| 2016-03-31 | $3.82 Trillion | -10.99% |
| 2015-03-31 | $4.30 Trillion | -5.97% |
| 2014-03-31 | $4.57 Trillion | +15.51% |
| 2013-03-31 | $3.96 Trillion | +10.58% |
| 2012-03-31 | $3.58 Trillion | +28.37% |
| 2011-03-31 | $2.79 Trillion | -1.31% |
| 2010-03-31 | $2.82 Trillion | +2.29% |
| 2009-03-31 | $2.76 Trillion | -3.13% |
| 2008-03-31 | $2.85 Trillion | -7.27% |
| 2007-03-31 | $3.07 Trillion | +0.99% |
| 2006-03-31 | $3.04 Trillion | +19.52% |
| 2005-03-31 | $2.55 Trillion | +8.98% |
| 2004-03-31 | $2.34 Trillion | +13.42% |
| 2003-03-31 | $2.06 Trillion | +4.79% |
| 2002-03-31 | $1.97 Trillion | +12.44% |
| 2001-03-31 | $1.75 Trillion | 0.00% |
| 2000-03-31 | $1.75 Trillion | -- |
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more